FGF21
The hepatic peptide hormone of fasting and ketogenic states — and the target behind the most exciting current NASH/MASH pipeline. Native FGF21 has a half-life measured in hours; the clinical drugs are engineered Fc-fusions and PEGylated variants dosed weekly.
What is FGF21?
FGF21 is a 181-amino-acid member of the fibroblast growth factor superfamily, produced predominantly by the liver under conditions of metabolic stress — prolonged fasting, ketogenic diets, protein restriction, mitochondrial dysfunction, and chronic alcohol exposure. Unlike canonical FGFs, it lacks the heparin-binding domain and functions as an endocrine (rather than paracrine) hormone, circulating and acting on distant tissues. It signals through FGFR1c paired with the co-receptor β-Klotho, expressed in adipose tissue, brain, pancreas, and liver. Metabolic effects include increased insulin sensitivity, hepatic fat reduction, increased adiponectin, and — uniquely among metabolic hormones — central effects on macronutrient preference (reduced sweet-food preference and reduced alcohol intake). Native FGF21 has a circulating half-life under two hours, so therapeutic development has focused on engineered long-acting analogs: efruxifermin (Fc-fusion), pegozafermin (PEGylated), aldafermin (FGF19 analog, mechanistically adjacent), BOS-580, and PF-05231023. The NASH/MASH pipeline is the leading clinical application, with efruxifermin's HARMONY Phase 2b data positioning it as a leading agent.
What FGF21 Is Investigated For
FGF21 has one of the strongest pipelines in contemporary metabolic medicine — the HARMONY Phase 2b trial of efruxifermin in NASH/MASH reported highly positive fibrosis-improvement data in 2023, with a 96-week follow-up published in 2025, and 89bio's pegozafermin has shown similar results in NASH plus pivotal data in severe hypertriglyceridemia. FGF21's uniqueness among metabolic hormones is its central action on macronutrient preference: the rodent data showing reduced sweet-food and reduced ethanol intake has translated, in early clinical work, to intriguing signals in alcohol-use-disorder populations. None of this translates to a legitimate self-administered use pattern — the clinically relevant agents are engineered biologics with weekly parenteral dosing, not available on the compounded-peptide market. Research-grade native FGF21 sold online is not the engineered therapeutic variant. The page is positioned as a biology and pipeline reference, not a dosing guide.
History & Discovery
FGF21 was identified and cloned around the turn of the 2000s as a novel member of the fibroblast growth factor superfamily with unusual properties — it lacked the heparin-binding domain that restricts canonical FGFs to paracrine signaling, it was produced mainly by the liver, and it had no obvious developmental or mitogenic role. Its biological function was unclear until Kharitonenkov and colleagues at Eli Lilly published the 2005 JCI paper demonstrating potent insulin-sensitizing and glucose-lowering effects in diabetic rodent and non-human primate models. That paper launched the therapeutic pipeline. The mechanistic biology was consolidated over the next few years. Inagaki and colleagues (2007 Cell Metabolism) showed that FGF21 is induced in the liver during fasting and ketogenic states through PPARα-driven transcription, positioning it as a key endocrine mediator of the adaptive starvation response. The β-Klotho co-receptor was identified as obligatory for FGF21 signaling, clarifying the tissue-specificity pattern. CNS effects on sweet-food and alcohol preference were mapped to hypothalamic β-Klotho-expressing neurons. The first-in-human trial of LY2405319 (an early Eli Lilly engineered variant) by Gaich and colleagues in 2013 confirmed metabolic effects in humans. Subsequent development focused on engineered long-acting variants with weekly dosing pharmacokinetics — efruxifermin (Akero's bivalent Fc-fusion), pegozafermin (89bio's PEGylated variant), aldafermin (NGM's FGF19 analog, mechanistically adjacent), BOS-580, and PF-05231023. The NASH indication emerged as the leading clinical target because of the combination of hepatic effects, metabolic benefit, and a regulatory context (FDA-endorsed surrogate endpoints) favorable to fibrosis-focused trials. The HARMONY Phase 2b trial of efruxifermin, read out in 2023, was the most consequential FGF21 clinical data to date, with the 96-week extension in 2025 supporting durability. Severe hypertriglyceridemia has emerged as a parallel indication for pegozafermin. Alcohol-use-disorder trials are an emerging area of interest.
How It Works
FGF21 is the hormone your liver makes when it thinks food is scarce — it rises in fasting, on keto diets, and in protein restriction. It tells adipose tissue to burn fat, tells the liver to make less fat, raises adiponectin (a marker of metabolic health), and — unusually — acts on the brain to reduce cravings for sweets and, in animal studies, for alcohol. The drugs in development (efruxifermin, pegozafermin) are engineered long-acting versions that exploit this biology for fatty liver disease. Native FGF21 is not used therapeutically because it breaks down too quickly.
FGF21 signals through FGFR1c (with lower-affinity activity at FGFR2c and FGFR3c) paired with the obligatory co-receptor β-Klotho, which is expressed in adipose tissue, pancreas, liver, and discrete CNS regions — most relevantly the hypothalamic paraventricular nucleus and suprachiasmatic nucleus. The tissue expression pattern of β-Klotho determines which tissues respond to circulating FGF21, distinguishing it from the canonical paracrine FGF signaling mode. Hepatic FGF21 transcription is driven by PPARα under fasting / ketogenic conditions and by ATF4 under mitochondrial stress and amino-acid imbalance. Peripheral effects include direct action on adipocytes to increase glucose uptake and adiponectin secretion (FGF21 elevates adiponectin robustly — this is one of its most reliable pharmacodynamic biomarkers), lipolysis regulation, and white-to-beige adipocyte browning (rodent data is clearer than human). Hepatic effects include reduced de novo lipogenesis and increased fatty-acid oxidation. CNS effects mediate suppression of sweet-food preference (via hypothalamic β-Klotho-expressing neurons) and reduced alcohol consumption (via central circuits that integrate reward and nutrient-sensing pathways). In obesity and NAFLD, serum FGF21 is paradoxically elevated — interpreted by some as a state of FGF21 resistance analogous to leptin resistance. Whether elevated baseline FGF21 in obese patients blunts response to therapeutic FGF21 analogs is partially supported by pharmacodynamic data but does not prevent therapeutic effect, because therapeutic exposures are far above physiologic levels and override the apparent resistance.
Evidence Snapshot
Human Clinical Evidence
Moderate-to-strong for NASH/MASH: efruxifermin HARMONY Phase 2b shows highly significant fibrosis improvement at 24 and 96 weeks, with pegozafermin showing similar results. Moderate for severe hypertriglyceridemia. Emerging for alcohol-use disorder. Weak for longevity or healthy-adult metabolic intervention — no trial in those populations has read out meaningfully.
Animal / Preclinical
Strong. FGF21 biology is extensively characterized across rodent and non-human-primate models. The discovery papers (Kharitonenkov 2005) and mechanistic work on fasting biology (Inagaki, Reitman) anchor a well-understood pathway.
Mechanistic Rationale
Strong. FGFR1c / β-Klotho signaling, PPARα-driven hepatic induction, and the adipose/hepatic/central action triad are thoroughly characterized.
Research Gaps & Open Questions
What the current literature has not yet settled about FGF21:
- 01Long-term (multi-year) safety of chronic FGF21-pathway stimulation, particularly bone-density effects.
- 02Whether fibrosis improvements on FGF21 therapy translate to reduced cirrhosis and hepatocellular carcinoma incidence over years — the definitive endpoint still awaits Phase 3 readouts.
- 03Whether CNS effects on alcohol and sweet-food preference translate to clinically meaningful use cases at doses tolerable for chronic administration.
- 04Whether combination with GLP-1 agonists produces synergistic rather than additive metabolic benefit in NASH and metabolic syndrome.
- 05Why obesity produces elevated baseline FGF21 — is this compensatory, dysregulatory, or incidental, and does it predict therapeutic response?
- 06Whether engineering of FGF21 analogs can separate the liver-beneficial actions from the bone-turnover signals seen in some programs.
- 07Role in longevity pathways — endogenous FGF21 rises in caloric restriction and ketogenic states, but whether chronic pharmacologic FGF21 elevation in healthy adults extends lifespan (as rodent CR models would predict) has not been tested.
Forms & Administration
Native FGF21 is not administered therapeutically — its half-life is too short (under 2 hours) for practical use. The engineered clinical analogs are subcutaneous injectables: efruxifermin is a bivalent Fc-fusion dosed weekly in NASH trials; pegozafermin is a PEGylated variant dosed weekly or every two weeks; aldafermin is mechanistically adjacent (FGF19 analog). BOS-580 and PF-05231023 are additional engineered variants in various trial stages. None are FDA-approved as of 2026. Research-chemical 'FGF21' sold online is native protein, not equivalent to the engineered therapeutic variants, and should not be presumed to reproduce the clinical-drug pharmacology.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
No FDA-approved FGF21 therapy exists. Clinical-trial dosing: efruxifermin 28 mg or 50 mg once weekly SC in NASH trials; pegozafermin 15 mg or 30 mg weekly or 44 mg every two weeks in NASH and severe-hypertriglyceridemia trials; aldafermin 1 mg daily SC in NASH (FGF19 analog, not FGF21 proper).
Frequency
Once weekly SC injection for efruxifermin-class Fc-fusion analogs; weekly or every-two-weeks for pegozafermin-class PEGylated variants. The engineered half-lives (multiple days to weeks) support these regimens. Native FGF21 at 1–2 hour half-life would require multiple-times-daily dosing.
Timing Considerations
Time of day
Not time-of-day specific — the engineered variants are weekly or biweekly and pharmacokinetically span multiple days.
Relative to meals
Not meal-timed in the clinical protocols; SC absorption is not meaningfully affected by food intake.
Relative to exercise
Not tied to exercise timing.
Weekly dosing schedules are typically fixed to a day of the week for convenience; no pharmacodynamic benefit to specific times has been established.
Protocol Notes
There is no legitimate at-home or compounded-peptide pathway for FGF21-class agents. The engineered therapeutics are investigational biologics administered in clinical trials. Research-grade native FGF21 sold online is not equivalent — the pharmacokinetic profile is fundamentally different, and its identity and purity are unverified. For readers interested in the biology as a guide to dietary intervention: endogenous FGF21 rises robustly in prolonged fasting (typically detectable after 36–72 hours) and during strict ketogenic-diet adherence, driven by PPARα. Whether dietary-induced FGF21 elevation produces metabolic benefits independent of the weight-loss effect of those interventions is unresolved. The engineered therapeutics produce 10–100× baseline elevations sustained over weeks — a far more intense pharmacology than dietary manipulation can reproduce.
FGF21 analogs are investigational biologics administered under clinical trial protocols. Nothing on this page constitutes a suggested self-use protocol, and no compounded-peptide source legitimately reproduces the engineered long-acting therapeutics.
Timeline of Effects
Onset
Metabolic biomarker responses (adiponectin elevation, triglyceride reduction) emerge within days to the first week of dosing in trial participants. Hepatic fat reduction on MRI-PDFF is typically detectable by 4–8 weeks. Fibrosis improvement on paired biopsy requires 24+ weeks of continuous dosing.
Peak Effect
Peak hepatic fat reduction is typically reached by 12–16 weeks of continuous efruxifermin dosing. Fibrosis improvement continues to accrue through week 96 per the HARMONY extension data. Adiponectin elevation reaches a plateau within 4–6 weeks.
After Discontinuation
Hepatic fat partially rebounds within weeks of discontinuation — the effect is pharmacologic and reversible, not disease-modifying in a durable sense without continued dosing. Fibrosis benefit accrual stops with discontinuation; whether established fibrosis improvement reverses on stopping is still being characterized in trial extensions.
Monitoring & Measurement
Bloodwork & Labs
- •Serum adiponectin — reliably rises on FGF21 therapy and is a well-validated pharmacodynamic marker
- •Serum FGF21 (ELISA) — elevated in NASH, fasting, and mitochondrial disease; rises further on engineered-analog therapy
- •Liver enzymes (ALT, AST) — decrease on FGF21-pathway therapy in NASH
- •Fasting triglycerides, HDL — respond favorably to FGF21-class agents
- •Bone-turnover markers (CTX, P1NP) — monitored in longer trials because of bone-density concerns
Functional & Performance Tests
- •MRI-PDFF (proton-density fat fraction) — primary imaging biomarker for hepatic steatosis
- •MR elastography or FibroScan — non-invasive fibrosis assessment
- •Liver biopsy with paired pre/post specimens — the regulatory endpoint for NASH fibrosis claims
When to Test
Baseline before initiation, with adiponectin and liver enzymes reassessed at 4–8 weeks, MRI-PDFF at 12–16 weeks, paired biopsy at 24+ weeks in NASH trials. Bone-turnover markers at baseline and every 6 months in longer-duration trials.
Interpretation & Notes
Serum FGF21 measurement is not clinically informative for most patients — absolute levels vary widely with fasting state, metabolic health, mitochondrial dysfunction, and alcohol intake. Adiponectin, by contrast, is the cleanest pharmacodynamic marker of FGF21-analog engagement: it rises reliably and dose-dependently, is easy to measure, and has well-characterized interpretation. MRI-PDFF is the gold-standard imaging biomarker for hepatic steatosis response and is the endpoint that most strongly correlates with clinical benefit in NASH. Liver biopsy remains the regulatory gold standard for fibrosis claims and is required for pivotal NASH endpoints.
Common Questions
Who FGF21 Is NOT For
- •No approved indication — investigational only. Clinical trial enrollment is the only legitimate pathway.
- •Active malignancy — FGF signaling has complex roles in cancer biology and is typically an exclusion criterion in trial protocols.
- •Pregnancy and lactation — insufficient data.
- •Patients with significant osteoporosis or recent fracture — bone-turnover signals in some programs prompt caution.
- •Known hypersensitivity to the specific agent's excipients or carrier proteins.
Drug & Supplement Interactions
Formal drug interaction studies with FGF21 analogs are limited because all agents are investigational. Theoretical and trial-protocol considerations: concurrent GLP-1 agonist use has been explored in NASH trial sub-studies and appears to produce complementary rather than antagonistic effects, though formal characterization is ongoing. Thyroid-axis interactions may be relevant because FGF21 modestly affects thyroid hormone metabolism. Glucose-lowering medications (insulin, sulfonylureas) may require dose reduction given FGF21's insulin-sensitizing effect, paralleling the interaction profile of GLP-1 agonists. FGF21 modestly affects bile-acid metabolism, which may have implications for oral contraceptive and statin pharmacokinetics, though this has not been systematically characterized at trial doses.
Safety Profile
Common Side Effects
Cautions
- • Bone-density monitoring is a consideration in long-term NASH trials because of concerns about TGF-β-family-adjacent signaling and bone-turnover shifts
- • Not appropriate in patients with active malignancy without oncology input
- • Interactions with other metabolic agents (GLP-1 agonists, thyroid hormones) not fully characterized
- • Pregnancy — insufficient human data across the pipeline
What We Don't Know
The long-term (multi-year) consequences of chronic FGF21-pathway stimulation are not yet characterized — the longest trial exposures are under two years. Whether the bone-turnover signals observed in some Phase 2 programs translate to clinically meaningful bone-density loss over years is unresolved. Whether the central alcohol- and sweet-preference effects observed in rodents translate robustly to humans at therapeutic doses awaits definitive trials.
Legal Status
United States
No FGF21-pathway agent is FDA-approved as of 2026. Efruxifermin, pegozafermin, aldafermin, BOS-580, and PF-05231023 are investigational. The FDA has granted Breakthrough Therapy Designation to multiple programs in NASH. Research-chemical 'FGF21' is not an FDA-regulated therapy.
International
Status parallels the US — investigational across the EU, UK, Japan, and other major markets. NASH / MASH regulatory frameworks differ slightly across regions but no approval has emerged as of 2026.
Sports & Competition
Peptide hormones and growth factors are covered under WADA's S2 class. FGF21 is not specifically named in current WADA prohibited-list entries but falls within the general category covering peptide hormones with metabolic effects. The practical reality is that no FGF21-class agent is commercially available, and access is trial-restricted.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
FGF21 is a fasting-mimetic peptide you can inject.
Reality
Native FGF21 has a half-life under two hours and would require impractical dosing frequency. The 'fasting-mimetic' framing oversimplifies — FGF21 is one component of a complex fasting adaptive response that also includes shifts in insulin, glucagon, cortisol, ketone bodies, autophagy, and more. Pharmacologic FGF21 monotherapy does not reproduce the full fasting state.
Myth
FGF21 is already approved for fatty liver disease.
Reality
As of 2026, no FGF21-pathway agent has FDA approval for NASH/MASH or any other indication. Efruxifermin and pegozafermin are in Phase 2b / Phase 3 development with highly positive 24- and 96-week data, but regulatory approval has not occurred.
Myth
FGF21 causes weight loss on the scale of GLP-1 agonists.
Reality
FGF21 analogs produce modest weight loss (typically 3–7% over trial periods) compared with the 10–20% weight loss seen with semaglutide and tirzepatide. The FGF21 weight-loss effect is secondary to its metabolic-improvement and hepatic-fat-reduction profile, not a primary indication. The NASH and hypertriglyceridemia indications do not depend on weight loss.
Myth
FGF21 blocks alcohol cravings in humans.
Reality
The rodent data is strong — FGF21 reduces ethanol consumption in mouse models with a mechanism mapped to hypothalamic β-Klotho-expressing neurons. Early human data are intriguing but small-scale and preliminary. Whether a therapeutic use case in alcohol-use disorder emerges from larger trials remains to be seen. The scientific interest is real, but the clinical claim is ahead of the evidence.
Myth
FGF21 is safer than GLP-1 agonists for metabolic indications.
Reality
Head-to-head comparative safety has not been established. FGF21 analogs have distinct adverse-event profiles — bone-turnover signals, adiponectin elevation, mild GI effects — that differ from GLP-1 side effects (nausea, gastroparesis, gallbladder issues). Each class has trade-offs; the 'safer' framing is marketing language that outruns the evidence.
Published Research
5 studiesSafety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
Noureddin et al. 2025 — the 96-week follow-up from HARMONY showing durability of fibrosis improvement on continued efruxifermin therapy. Key longer-term data supporting the ongoing Phase 3 NASH program.
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
Harrison et al. 2023 Lancet — the HARMONY Phase 2b trial of efruxifermin (Akero Therapeutics) in NASH, showing fibrosis improvement at 24 weeks with a clinically meaningful effect size. The reference point for current FGF21-pathway NASH development.
Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21
Inagaki et al. 2007 Cell Metabolism — established that hepatic FGF21 induction under fasting conditions is driven by PPARα and coordinates the adaptive ketogenic response. A core mechanism paper for the fasting-biology framing of FGF21.
FGF21: a missing link in the biology of fasting
Reitman 2007 Cell Metabolism — commentary in the same issue as Inagaki, framing FGF21's role as the fasting-response hepatokine. A frequently cited reference for the physiological interpretation of FGF21 biology.
FGF-21 as a novel metabolic regulator
Kharitonenkov et al. 2005 Journal of Clinical Investigation — the foundational paper establishing FGF21 as a therapeutic metabolic-regulator candidate, showing insulin-sensitizing and glucose-lowering effects in diabetic rodents and primates. The paper that launched the clinical pipeline.
Quick Facts
- Class
- Hepatokine
- Evidence
- Moderate
- Safety
- Moderate Data
- Updated
- Apr 2026
- Citations
- 5PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.